12:54:46 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-02-21 Bokslutskommuniké 2023
2023-11-13 Extra Bolagsstämma 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-08-04 Kvartalsrapport 2023-Q2
2023-07-03 Ordinarie utdelning IRRAS 0.00 SEK
2023-06-30 Årsstämma 2023
2023-05-17 Kvartalsrapport 2023-Q1
2023-02-16 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-07-22 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning IRRAS 0.00 SEK
2022-05-24 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-16 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-07-15 Extra Bolagsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2021-04-28 Årsstämma 2021
2021-02-16 Bokslutskommuniké 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-14 Kvartalsrapport 2020-Q1
2020-04-29 Ordinarie utdelning IRRAS 0.00 SEK
2020-04-28 Årsstämma 2020
2020-03-02 Extra Bolagsstämma 2020
2020-02-14 Bokslutskommuniké 2019
2019-11-08 Kvartalsrapport 2019-Q3
2019-08-29 Kvartalsrapport 2019-Q2
2019-05-15 Ordinarie utdelning IRRAS 0.00 SEK
2019-05-15 Kvartalsrapport 2019-Q1
2019-05-14 Årsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-07 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2018-06-04 Ordinarie utdelning IRRAS 0.00 SEK
2018-05-29 Kvartalsrapport 2018-Q1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
IRRAS är verksamt inom medicinteknik. Bolaget är inriktade mot att utveckla lösningar för kirurgiska ingrepp vid hjärnsjukdomar. Bolaget har för närvarande utvecklat en teknologisk plattform som fokuserar på hantering av en rad delmoment vid hemorragisk stroke och kronisk subduralhematom, främst vid vätskehantering och intrakraniella blödningar. Bolaget har sitt huvudkontor i Stockholm.
2021-11-09 08:00:00

Fifth Consecutive Quarter of Revenue Growth

"Q3 marked our company's 5th consecutive quarter of growth, even with increased impact during the quarter from the COVID-19 Delta variant. This growth and the strengthening foundation of our business show that IRRAS is well positioned to continue this positive growth trajectory."

"We are pleased with our accomplishments during the third quarter of 2021, and our continued progress across the key elements of our business - revenue growth, operational efficiency, and clinical data generation - confirms our forward momentum."

Will Martin, President and CEO of IRRAS

Third Quarter, July - September 2021, Results
  • Net revenue amounted to SEK 6.1 million (2.1)
  • Operating loss (EBIT) amounted to SEK -27.0 million (-31.0)
  • Loss after tax amounted to SEK -26.9 million (-31.0)
  • Earnings per share before and after dilution amounted to SEK -0.34 (-0.47)
Period, January - September 2021, Results
  • Net revenue amounted to SEK 15.2 million (4.9)
  • Operating loss (EBIT) amounted to SEK -93.0 million (-97.5)
  • Loss after tax amounted to SEK -92.9 million (-97.8)
  • Earnings per share before and after dilution amounted to SEK -1.30 (-1.90)

Important events during the quarter

Company Leadership Transition Completed
  • On July 1, Will Martin assumed the role of IRRAS President & Chief Executive Officer.  Kleanthis G. Xanthopoulos, Ph.D. remains on the company's Board of Directors.
Loan Financing Completed via European Investment Bank
  • IRRAS signed a 10M EUR loan agreement that provides non-dilutive financing for IRRAS to fund product development and clinical data generation activities being performed in the EU.
Ventriculitis Case Study Published
  • Helsinki University Hospital published a case series that confirmed the ability of IRRAflow to treat patients with pyogenic ventriculitis, an aggressive brain infection.
  • Publication documents the ability of IRRAflow to directly deliver antibiotics into the intracranial space for the first time in peer-reviewed literature.
Expanded Quality System Certifications Received after Onsite Inspection
  • IRRAS' in-house manufacturing facility for IRRAflow capital equipment was added to its ISO 13485:2016 certification, and the company's MDSAP certificate was extended for 3 years.

Important events after the end of the quarter

CE Mark certification received for enhanced IRRAflow Drainage Catheter
  • Enhanced catheter with improved kink resistance and increased drainage capabilities now available for patient treatments in Europe.
ACTIVE clinical study initiated by Aarhus University Hospital
  • Aarhus University Hospital, a leading hospital in Denmark, began commercial patient treatments with IRRAflow and will capture its results in the ACTIVE investigator-initiated clinical trial to prove the system's superiority versus traditional drainage systems.
First patients enrolled in ARCH clinical study
  • Dr. Behnam Rezai Jahromi from Helsinki University Hospital enrolled the first patients in the ARCH clinical study, which compares use of IRRAflow with clot-busting medication versus traditional drainage systems in patients with intraventricular hemorrhage.

The report is available on the company's website:  https://investors.irras.com/en/reports-presentations.

About IRRAS

IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.  

IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com. 

IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).

For more information, please contact:

USA
Will Martin
President and CEO
ir@irras.com

Europe

Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172

This document is considered information that IRRAS is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on November 9, 2021 at 8:00 a.m. (CET).